| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
- |
| Employees |
181 |
| Revenues (TTM) (Millions $) |
10 |
| Net Income (TTM) (Millions $) |
-55 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Innate Pharma SA is a biotechnology company based in France. The company focuses on discovering and developing therapeutic antibodies for the treatment of cancer and inflammatory diseases. Innate Pharma's research is centered around natural killer (NK) cell biology and tumor microenvironment.
The company's proprietary technology platform, called IPH4102, targets the KIR3DL2 receptor, which is expressed in various hematological malignancies. Innate Pharma is also involved in developing other antibodies targeting immune checkpoints, as well as modulating the tumor microenvironment to enhance immune responses against cancer.
Innate Pharma collaborates with various pharmaceutical companies and academic institutions to advance its research and development programs. The company has a pipeline of product candidates in different stages of clinical development, including monotherapy and combination therapies.
Overall, Innate Pharma aims to leverage its expertise in immune biology to develop innovative treatments for patients with cancer and inflammatory diseases.
Company Address: 117, Avenue de Luminy Marseille 13009
Company Phone Number: 4 30 30 30 30 Stock Exchange / Ticker: NASDAQ IPHA
|
2.03% 
6.89 %